T. Rowe Price Associates
ATXS

T. Rowe Price Associates’s Astria Therapeutics ATXS Stock Holding History

T. Rowe Price Associates’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,810
Closed -$286K – 3138
2025
Q4 		$286K Buy
21,810
+2,191
+11% +$26.2K ﹤0.01% 2665
2025
Q3 		$143K Sell
19,619
-1,898
-9% -$12.8K ﹤0.01% 2863
2025
Q2 		$116K Buy
21,517
+1,327
+7% +$6.43K ﹤0.01% 2864
2025
Q1 		$108K Buy
20,190
+2,428
+14% +$17K ﹤0.01% 2805
2024
Q4 		$159K Buy
17,762
+2,878
+19% +$30.6K ﹤0.01% 2756
2024
Q3 		$164K Hold
14,884
– – ﹤0.01% 2713
2024
Q2 		$136K Buy
14,884
+681
+5% +$6.65K ﹤0.01% 2692
2024
Q1 		$200K Buy
+14,203
New +$177K ﹤0.01% 2624
2021
Q4 		– Sell
-11,966
Closed -$106K – 2984
2021
Q3 		$106K Sell
11,966
-1
-0% -$10 ﹤0.01% 2833
2021
Q2 		$151K Sell
11,967
-238
-2% -$3.09K ﹤0.01% 2782
2021
Q1 		$212K Buy
+12,205
New +$220K ﹤0.01% 2671

T. Rowe Price Associates's ATXS Position: Q1 2026 in Review

T. Rowe Price Associates sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 21,810 shares — an estimated $286K sold.

T. Rowe Price Associates first reported a position in ATXS in Q1 2021 and held it in 11 quarters. The position peaked at $286K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

  • T. Rowe Price Associates reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 21,810 Astria Therapeutics shares in Q1 2026, an estimated $286K.
  • T. Rowe Price Associates first reported a position in Astria Therapeutics in Q1 2021 and held it in 11 quarters.
  • T. Rowe Price Associates's Astria Therapeutics position peaked at $286K in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.